PALATIN TECHNOLOGIES, INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.71 USD | -1.16% |
|
-9.52% | -57.04% |
Presentation Operator MessageOperator (Operator)Greetings. Welcome to Palatin's Third Quarter ...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Palatin Technologies, Inc. is a biopharmaceutical company. The Company is engaged in developing medicines based on molecules that modulate the activity of the melanocortin receptor systems, with targeted, receptor-specific product candidates for the treatment of diseases with unmet medical need and commercial potential. Its new product development activities focus primarily on MC1r agonists, with potential to treat inflammatory and autoimmune diseases, such as dry eye disease, known as keratoconjunctivitis sicca, uveitis, diabetic retinopathy, and inflammatory bowel disease. It is also engaged developing peptides that are active at more than one melanocortin receptor, and MC4r peptide and small molecule agonists with potential utility in obesity and metabolic-related disorders, including rare disease and orphan indications. It has completed Phase III PL9643 clinical study for dry eye disease. It is also conducting Phase II study of oral PL8177 in patients with ulcerative colitis.
Calendar
2024-05-13
- Q3 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1.73
USD
Average target price
9.333
USD
Spread / Average Target
+439.50%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -57.04% | 27.92M | |
| -2.07% | 104B | |
| +1.78% | 97.42B | |
| +0.79% | 22.2B | |
| -17.79% | 21.23B | |
| -11.11% | 18.33B | |
| -42.83% | 16.35B | |
| -16.58% | 15.06B | |
| +3.61% | 13.98B | |
| +33.44% | 11.66B |
- Stock Market
- Equities
- PTN Stock
- News Palatin Technologies, Inc.
- Transcript : Palatin Technologies, Inc., Q3 2023 Earnings Call, May 16, 2023
